Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction

Norihiro Nagai, Pete Lundh von Leithner, Kanako Izumi-Nagai, Brett Hosking, Bo Chang, Ron Hurd, Peter Adamson, Anthony P. Adamis, Richard H. Foxton, Yin Shan Ng, David T. Shima

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose. Characterization of a mouse model of spontaneous choroidal neovascularization (sCNV) and its effect on retinal architecture and function. Methods. The sCNV mouse phenotype was characterized by using fundus photography, fluorescein angiography, confocal scanning laser ophthalmoscopy (SLO), optical coherence tomography (OCT), ERG, immunostaining, biochemistry, and electron microscopy. A role for VEGF-A signaling in sCNV was investigated by using neutralizing antibodies and a role for macrophages explored by cell-depletion studies. Results. The sCNV starts between postnatal day 10 and 15 (P10-P15), increasing in number and severity causing RPE disruption and dysfunction. Various morphological methods confirmed the choroidal origin and subretinal position of the angiogenic vessels. At approximately P25, vessels were present in the outer retina with instances of anastomosis of some sCNV lesions with the retinal vasculature. The number of CNV lesions was significantly decreased by systemic blockade of the VEGF-A pathway. Choroidal neovascularization size also was significantly modulated by reducing the number of lesion-associated macrophages. Later stages of sCNV were associated with edema, neuronal loss, and dysfunction. Conclusions. The sCNV mouse is a new model for the study of both early and late events associated with choroidal neovascularization. Pharmacological reduction in sCNV with VEGFA antagonists and an anti-inflammatory strategy suggests the model may be useful for investigating novel targets for treating human ocular neovascular disease.

Original languageEnglish
Pages (from-to)3709-3719
Number of pages11
JournalInvestigative Ophthalmology and Visual Science
Volume55
Issue number6
DOIs
Publication statusPublished - 2014 May 20
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Edema
Macrophages
Ophthalmoscopy
Eye Diseases
Fluorescein Angiography
Photography
Optical Coherence Tomography
Neutralizing Antibodies
Biochemistry
Retina
Electron Microscopy
Lasers
Anti-Inflammatory Agents
Pharmacology
Phenotype

Keywords

  • Animal models
  • Neovascularization
  • VEGF-A

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. / Nagai, Norihiro; von Leithner, Pete Lundh; Izumi-Nagai, Kanako; Hosking, Brett; Chang, Bo; Hurd, Ron; Adamson, Peter; Adamis, Anthony P.; Foxton, Richard H.; Ng, Yin Shan; Shima, David T.

In: Investigative Ophthalmology and Visual Science, Vol. 55, No. 6, 20.05.2014, p. 3709-3719.

Research output: Contribution to journalArticle

Nagai, N, von Leithner, PL, Izumi-Nagai, K, Hosking, B, Chang, B, Hurd, R, Adamson, P, Adamis, AP, Foxton, RH, Ng, YS & Shima, DT 2014, 'Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction', Investigative Ophthalmology and Visual Science, vol. 55, no. 6, pp. 3709-3719. https://doi.org/10.1167/iovs.14-13989
Nagai, Norihiro ; von Leithner, Pete Lundh ; Izumi-Nagai, Kanako ; Hosking, Brett ; Chang, Bo ; Hurd, Ron ; Adamson, Peter ; Adamis, Anthony P. ; Foxton, Richard H. ; Ng, Yin Shan ; Shima, David T. / Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. In: Investigative Ophthalmology and Visual Science. 2014 ; Vol. 55, No. 6. pp. 3709-3719.
@article{6de1292697814964b70fc2380788e13e,
title = "Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction",
abstract = "Purpose. Characterization of a mouse model of spontaneous choroidal neovascularization (sCNV) and its effect on retinal architecture and function. Methods. The sCNV mouse phenotype was characterized by using fundus photography, fluorescein angiography, confocal scanning laser ophthalmoscopy (SLO), optical coherence tomography (OCT), ERG, immunostaining, biochemistry, and electron microscopy. A role for VEGF-A signaling in sCNV was investigated by using neutralizing antibodies and a role for macrophages explored by cell-depletion studies. Results. The sCNV starts between postnatal day 10 and 15 (P10-P15), increasing in number and severity causing RPE disruption and dysfunction. Various morphological methods confirmed the choroidal origin and subretinal position of the angiogenic vessels. At approximately P25, vessels were present in the outer retina with instances of anastomosis of some sCNV lesions with the retinal vasculature. The number of CNV lesions was significantly decreased by systemic blockade of the VEGF-A pathway. Choroidal neovascularization size also was significantly modulated by reducing the number of lesion-associated macrophages. Later stages of sCNV were associated with edema, neuronal loss, and dysfunction. Conclusions. The sCNV mouse is a new model for the study of both early and late events associated with choroidal neovascularization. Pharmacological reduction in sCNV with VEGFA antagonists and an anti-inflammatory strategy suggests the model may be useful for investigating novel targets for treating human ocular neovascular disease.",
keywords = "Animal models, Neovascularization, VEGF-A",
author = "Norihiro Nagai and {von Leithner}, {Pete Lundh} and Kanako Izumi-Nagai and Brett Hosking and Bo Chang and Ron Hurd and Peter Adamson and Adamis, {Anthony P.} and Foxton, {Richard H.} and Ng, {Yin Shan} and Shima, {David T.}",
year = "2014",
month = "5",
day = "20",
doi = "10.1167/iovs.14-13989",
language = "English",
volume = "55",
pages = "3709--3719",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "6",

}

TY - JOUR

T1 - Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction

AU - Nagai, Norihiro

AU - von Leithner, Pete Lundh

AU - Izumi-Nagai, Kanako

AU - Hosking, Brett

AU - Chang, Bo

AU - Hurd, Ron

AU - Adamson, Peter

AU - Adamis, Anthony P.

AU - Foxton, Richard H.

AU - Ng, Yin Shan

AU - Shima, David T.

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Purpose. Characterization of a mouse model of spontaneous choroidal neovascularization (sCNV) and its effect on retinal architecture and function. Methods. The sCNV mouse phenotype was characterized by using fundus photography, fluorescein angiography, confocal scanning laser ophthalmoscopy (SLO), optical coherence tomography (OCT), ERG, immunostaining, biochemistry, and electron microscopy. A role for VEGF-A signaling in sCNV was investigated by using neutralizing antibodies and a role for macrophages explored by cell-depletion studies. Results. The sCNV starts between postnatal day 10 and 15 (P10-P15), increasing in number and severity causing RPE disruption and dysfunction. Various morphological methods confirmed the choroidal origin and subretinal position of the angiogenic vessels. At approximately P25, vessels were present in the outer retina with instances of anastomosis of some sCNV lesions with the retinal vasculature. The number of CNV lesions was significantly decreased by systemic blockade of the VEGF-A pathway. Choroidal neovascularization size also was significantly modulated by reducing the number of lesion-associated macrophages. Later stages of sCNV were associated with edema, neuronal loss, and dysfunction. Conclusions. The sCNV mouse is a new model for the study of both early and late events associated with choroidal neovascularization. Pharmacological reduction in sCNV with VEGFA antagonists and an anti-inflammatory strategy suggests the model may be useful for investigating novel targets for treating human ocular neovascular disease.

AB - Purpose. Characterization of a mouse model of spontaneous choroidal neovascularization (sCNV) and its effect on retinal architecture and function. Methods. The sCNV mouse phenotype was characterized by using fundus photography, fluorescein angiography, confocal scanning laser ophthalmoscopy (SLO), optical coherence tomography (OCT), ERG, immunostaining, biochemistry, and electron microscopy. A role for VEGF-A signaling in sCNV was investigated by using neutralizing antibodies and a role for macrophages explored by cell-depletion studies. Results. The sCNV starts between postnatal day 10 and 15 (P10-P15), increasing in number and severity causing RPE disruption and dysfunction. Various morphological methods confirmed the choroidal origin and subretinal position of the angiogenic vessels. At approximately P25, vessels were present in the outer retina with instances of anastomosis of some sCNV lesions with the retinal vasculature. The number of CNV lesions was significantly decreased by systemic blockade of the VEGF-A pathway. Choroidal neovascularization size also was significantly modulated by reducing the number of lesion-associated macrophages. Later stages of sCNV were associated with edema, neuronal loss, and dysfunction. Conclusions. The sCNV mouse is a new model for the study of both early and late events associated with choroidal neovascularization. Pharmacological reduction in sCNV with VEGFA antagonists and an anti-inflammatory strategy suggests the model may be useful for investigating novel targets for treating human ocular neovascular disease.

KW - Animal models

KW - Neovascularization

KW - VEGF-A

UR - http://www.scopus.com/inward/record.url?scp=84902479452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902479452&partnerID=8YFLogxK

U2 - 10.1167/iovs.14-13989

DO - 10.1167/iovs.14-13989

M3 - Article

C2 - 24845632

AN - SCOPUS:84902479452

VL - 55

SP - 3709

EP - 3719

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 6

ER -